Circular RNA
Revolutionary
C3RNA Technology:
The Future of Vaccines and Therapeutics
At Sekkei Bio, we’re pioneering C3RNA (Circular, Clean, Continuous) – a groundbreaking circular RNA technology poised to transform the biological landscape.
Our Proprietary Platform Offers
-
Enhanced stability
and efficacy
- Reduced development timelines
-
Lower production
costs
-
Improved
accessibility
Partnering for Excellence
Leveraging our cutting-edge Sq suite design tool, we’re creating novel immunogens and therapeutics with unparalleled potential. Our RSV vaccine program, supported by the Bill & Melinda Gates Foundation, showcases the power of C3RNA in addressing global health challenges.
Expression Systems
Pichia pastoris and Escherichia coli are widely used for protein production, each with unique advantages. Pichia pastoris, a methylotrophic yeast, offers cost-effective protein production with complex post-translational modifications like glycosylation and phosphorylation. It utilizes strong promoters for enhanced protein expression, producing high yields of secreted, fully folded proteins. Expertise in construct design and selection of high-yield, methanol-tolerant clones ensure the creation of valuable cell banks for large-scale production. Fast, flexible workflows facilitate lab-scale process development, allowing rapid production of purified material for characterization.
Escherichia coli is known for its simplicity, rapid growth, and ease of genetic manipulation. It allows for fast production cycles and high expression levels, making it ideal for basic research, enzyme and peptide production, industrial biotechnology, and protein structure studies. Together, these systems accelerate peptide-based product development across various biotechnology applications.
Figure. Different approaches to predefine the delivery strategies for Peptides.
Circular RNA delivery – RNA-based products have been delivered by encapsulation in lipid nanoparticles (LNPs). They use a combination of cationic ionizable lipids, helper lipids, PEG lipid, and cholesterol to encapsulate large amounts of RNA for targeted delivery. Sekkei Bio is developing differentiated LNP technology, both lipid and non-lipid based, specifically for circular RNA delivery. The aim is to develop efficient delivery systems for both circular RNA based vaccines and for circular RNA based therapeutics.
Novel Formulation Development
Oral peptide delivery faces challenges due to enzymatic degradation, poor membrane permeability, and short half-life. Effective formulations aim to protect peptides, enhance stability, and improve bioavailability. Innovative strategies, including novel drug delivery carriers and permeation enhancers, are crucial. Computational methods using molecular modeling, simulations, and machine learning optimize these enhancers. Our approach involves conjugating or encapsulating peptides with permeation enhancers to improve gut mucosa absorption.
Lipid Nanoparticles
Lipid nanoparticles are a groundbreaking and efficient technology for delivering RNA-based vaccines and therapeutics. They use a combination of cationic ionizable lipids, helper lipids, PEG lipid, and cholesterol to encapsulate large amounts of RNA for targeted delivery. Recent advancements in particle engineering are enhancing RNA therapeutic delivery.
Sekkei is developing cutting-edge LNP technology for RNA delivery, offering superior encapsulation, stability, and targeted delivery. These LNPs can be used for various biotherapeutics, including siRNA, mRNA, circRNA, antibodies, therapeutic proteins, and peptides. Additionally, Sekkei is also working on polymer-based nanoparticles, such as PLGA and chitosan, to improve gene delivery alternatives.
Sekkei Bio is seeking innovation partners to build
pharmaceutical technologies to revolutionize patient care.
pharmaceutical technologies to revolutionize patient care.